RxDoctor Payments Data

Hillary McDonald, PA

Physician Assistant · Brandywine, MDNPI 1063050953

Payments from drug & device makers

$8,818in general payments, 2019–2025

Across 352 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • AbbVie$812
  • Astellas Pharma US Inc$752
  • Johnson & Johnson$738
  • Pfizer$625
  • Sumitomo Pharma America, Inc.$385
  • plus $4K from 45 others

What the payments were for

  • Travel & lodging$6457%
  • Food & beverage$7,50785%
  • Education$6517%
  • Gifts$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,818 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$316,464
Medicare patients
557
Services billed
10,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide66$1,108,467
GemtesaVibegron37$28,088
MyrbetriqMirabegron23$23,585
Tamsulosin Hcl176$2,067
Testosterone11$1,697
Estradiol17$1,565
Finasteride123$1,545
Solifenacin Succinate28$1,237
Silodosin15$1,064
Methenamine Hippurate17$1,048
Potassium Citrate ErPotassium Citrate11$951
Trospium Chloride11$895
Oxybutynin Chloride ErOxybutynin Chloride38$573
Dutasteride15$266
Albuterol Sulfate HfaAlbuterol Sulfate11$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$752$1,132,05289 claims
Sumitomo Pharma America, Inc.Gemtesa$385$28,08837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Brandywine

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →